share_log

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

BioMarin 製藥公司s(納斯達克股票代碼:BMRN)股票處於上升趨勢:基本面能否推動勢頭?
Simply Wall St ·  01/18 07:08

BioMarin Pharmaceutical (NASDAQ:BMRN) has had a great run on the share market with its stock up by a significant 14% over the last three months. We wonder if and what role the company's financials play in that price change as a company's long-term fundamentals usually dictate market outcomes. Particularly, we will be paying attention to BioMarin Pharmaceutical's ROE today.

BioMarin Pharmaceutical(納斯達克股票代碼:BMRN)在股票市場上表現良好,其股票在過去三個月中大幅上漲了14%。我們想知道公司的財務狀況在價格變動中是否起着什麼作用,因爲公司的長期基本面通常決定市場業績。特別是,我們今天將關注BioMarin製藥的投資回報率。

Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Put another way, it reveals the company's success at turning shareholder investments into profits.

股本回報率或投資回報率是股東需要考慮的重要因素,因爲它可以告訴他們資本再投資的有效性。換句話說,它揭示了公司成功地將股東投資轉化爲利潤。

See our latest analysis for BioMarin Pharmaceutical

查看我們對 BioMarin Pharmaceutical 的最新分析

How To Calculate Return On Equity?

如何計算股本回報率?

The formula for ROE is:

ROE 的公式是:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

股本回報率 = 淨利潤(來自持續經營業務)÷ 股東權益

So, based on the above formula, the ROE for BioMarin Pharmaceutical is:

因此,根據上述公式,BioMarin製藥的投資回報率爲:

3.0% = US$147m ÷ US$4.9b (Based on the trailing twelve months to September 2023).

3.0% = 1.47億美元 ÷ 49億美元(基於截至2023年9月的過去十二個月)。

The 'return' is the yearly profit. So, this means that for every $1 of its shareholder's investments, the company generates a profit of $0.03.

“回報” 是每年的利潤。因此,這意味着其股東每投資1美元,公司就會產生0.03美元的利潤。

What Is The Relationship Between ROE And Earnings Growth?

投資回報率與收益增長之間有什麼關係?

So far, we've learned that ROE is a measure of a company's profitability. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.

到目前爲止,我們已經了解到,投資回報率是衡量公司盈利能力的指標。根據公司選擇將多少利潤進行再投資或 “保留”,我們便能夠評估公司未來創造利潤的能力。假設其他一切保持不變,那麼與不一定具有這些特徵的公司相比,投資回報率和利潤保留率越高,公司的增長率就越高。

BioMarin Pharmaceutical's Earnings Growth And 3.0% ROE

BioMarin 製藥的收益增長和 3.0% 的投資回報率

It is hard to argue that BioMarin Pharmaceutical's ROE is much good in and of itself. Even compared to the average industry ROE of 18%, the company's ROE is quite dismal. Although, we can see that BioMarin Pharmaceutical saw a modest net income growth of 14% over the past five years. We believe that there might be other aspects that are positively influencing the company's earnings growth. For instance, the company has a low payout ratio or is being managed efficiently.

很難說BioMarin Pharmaceutical的投資回報率本身就非常好。即使與18%的行業平均投資回報率相比,該公司的投資回報率也相當慘淡。但是,我們可以看到,在過去五年中,BioMarin製藥的淨收入略有增長14%。我們認爲,可能還有其他方面對公司的收益增長產生積極影響。例如,該公司的派息率較低或管理效率很高。

We then compared BioMarin Pharmaceutical's net income growth with the industry and found that the company's growth figure is lower than the average industry growth rate of 18% in the same 5-year period, which is a bit concerning.

然後,我們將BioMarin Pharmaceutical的淨收入增長與該行業進行了比較,發現該公司的增長數字低於同期18%的行業平均增長率,這有點令人擔憂。

past-earnings-growth
NasdaqGS:BMRN Past Earnings Growth January 18th 2024
納斯達克GS:BMRN過去的收益增長 2024年1月18日

The basis for attaching value to a company is, to a great extent, tied to its earnings growth. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). This then helps them determine if the stock is placed for a bright or bleak future. If you're wondering about BioMarin Pharmaceutical's's valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.

爲公司附加價值的基礎在很大程度上與其收益增長息息相關。對於投資者來說,重要的是要知道市場是否對公司的預期收益增長(或下降)進行了定價。然後,這可以幫助他們確定股票是面向光明還是暗淡的未來。如果你想知道BioMarin Pharmaceutical的估值,可以看看這個衡量其與行業相比的市盈率指標。

Is BioMarin Pharmaceutical Using Its Retained Earnings Effectively?

BioMarin Pharmaceutical 能否有效使用其留存收益?

BioMarin Pharmaceutical doesn't pay any dividend currently which essentially means that it has been reinvesting all of its profits into the business. This definitely contributes to the decent earnings growth number that we discussed above.

BioMarin Pharmaceutical目前不支付任何股息,這實質上意味着它一直在將所有利潤再投資於該業務。這無疑有助於實現我們上面討論的可觀的收入增長數字。

Summary

摘要

In total, it does look like BioMarin Pharmaceutical has some positive aspects to its business. That is, a decent growth in earnings backed by a high rate of reinvestment. However, we do feel that that earnings growth could have been higher if the business were to improve on the low ROE rate. Especially given how the company is reinvesting a huge chunk of its profits. With that said, the latest industry analyst forecasts reveal that the company's earnings are expected to accelerate. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.

總的來說,看來BioMarin Pharmaceutical的業務確實有一些積極的方面。也就是說,在高再投資率的支持下,收益的體面增長。但是,我們確實認爲,如果業務在較低的投資回報率基礎上有所改善,收益增長本來可以更高。特別是考慮到該公司正在將很大一部分利潤再投資。話雖如此,最新的行業分析師預測顯示,該公司的收益有望加速。要了解有關公司未來收益增長預測的更多信息,請查看這份免費的分析師預測報告,以了解更多信息。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論